One major concern is muscle loss
Meanwhile, findings of a 2021 clinical trial published in JAMA showed that after discontinuing a GLP-1 after 20 weeks, individuals gained back 6.9% of their weight after another 48 weeks
What we found Our analysis of semaglutide, tirzepatide, and pembrolizumab included 575 shipments in total
This distinction matters in the GLP-1 market, as regulatory scrutiny, quality controls, and allowable production practices vary significantly between the two models and, as of April 2026, the two tiers face meaningfully different enforcement exposure
Winzeler B et al (2020) Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers
(2015) found that H 2 -rich saline inhibited the activation of crucial inflammatory signaling pathway NF-B and reduced serum IL-1, IL-6, and TNF- levels, thus alleviating the airway inflammatory response caused by a burn in rats